| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 26.04.
| Swedish Orphan Biovitrum AB (publ): Sobi:Resolutions from Swedish Orphan Biovitrum's ("Sobi") Annual General Meeting (AGM) | | 41 | Thomson Reuters ONE |
| The Sobi AGM convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including: Adoption of the profit and loss statements and balance sheet and discharge...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi:Resolutions from Swedish Orphan Biovitrum's ("Sobi") Annual General Meeting (AGM) | |
| 26.04.
| Swedish Orphan Biovitrum AB (publ): Sobi : Interim Report, January - March 2012 | | 30 | Thomson Reuters ONE |
| Geoffrey McDonough, CEO: "The first quarter marks a solid beginning for 2012 with consistent growth across our product business lines. We finalized two significant transactions with Pfizer and made...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi : Interim Report, January - March 2012 | |
| 24.04.
| Swedish Orphan Biovitrum AB (publ): Sobi: The board of directors exercises authorization for share issuance and repurchase of shares | | 39 | Thomson Reuters ONE |
| - for the purpose of securing the company's commitments under the performance based, long-term share programs The Extraordinary General Meeting of Swedish Orphan Biovitrum AB (publ) on 24 August 2011...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi: The board of directors exercises authorization for share issuance and repurchase of shares | |
| 17.04.
| Swedish Orphan Biovitrum AB (publ): Sobi: Invitation - Presentation of first quarter results | | 29 | Thomson Reuters ONE |
| Sobi's interim report for the first quarter of 2012 will be published on 26 April 2012 at 8.30 a.m. CET. Conference call at 2.00 p.m. CETFinancial analysts and media are invited to a telephone conference...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi: Invitation - Presentation of first quarter results | |
| 05.04.
| Swedish Orphan Biovitrum AB (publ): Sobi's Annual Report published on the web | | 60 | Thomson Reuters ONE |
| Swedish Orphan Biovitrum's Annual Report for 2011 has now been published on the Company's website www.sobi.com (http://www.sobi.com/) under Investors & Media/ Interim and Annual Reports. Swedish...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi's Annual Report published on the web | |
| 30.03.
| Swedish Orphan Biovitrum AB (publ): Sobi amends its agreement with sellers of Arexis AB | | 27 | Thomson Reuters ONE |
| Sobi has amended its share purchase agreement regarding the acquisition in 2005 of the pharmaceutical company Arexis AB, which included a number of development programs. According to the amended agreement...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi amends its agreement with sellers of Arexis AB | |
| 26.03.
| Swedish Orphan Biovitrum AB (p: Notice of annual general meeting in Swedish Orp... | | - | InvestEgate |
| 26.03.
| Swedish Orphan Biovitrum AB (publ): Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) | | 46 | Thomson Reuters ONE |
| The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"), to be held on Thursday 26 April 2012 at 4.00 p.m. in...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) | |
| 20.03.
| Swedish Orphan Biovitrum AB (p: CFO Lars Sandström to leave Sobi | | 2 | InvestEgate |
| 20.03.
| Swedish Orphan Biovitrum AB (publ): CFO Lars Sandström to leave Sobi | | 26 | Thomson Reuters ONE |
| CFO Lars Sandström will leave Sobi during the summer 2012 to return to his former employer Scania. The recruitment of a new CFO has been initiated. Lars Sandström joined Sobi in 2010 and was appointed...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): CFO Lars Sandström to leave Sobi | |
| 23.02.
| Swedish Orphan Biovitrum AB (p: Sobi: Report for the Fourth Quarter and Full Ye... | | 1 | InvestEgate |
| 23.02.
| Swedish Orphan Biovitrum AB (publ): Sobi: Report for the Fourth Quarter and Full Year 2011 | | 41 | Thomson Reuters ONE |
| Â Geoffrey McDonough, CEO: "2011 was a year of consolidation and stabilization for Sobi. Our full year results show revenues in line with the previous year, with impact from currency and discontinued...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi: Report for the Fourth Quarter and Full Year 2011 | |
| 17.02.
| Swedish Orphan Biovitrum AB (publ): Sobi: Presentation of Q4 and Full Year 2011 results | | 37 | Thomson Reuters ONE |
| Sobi's interim report for the fourth quarter and full year 2011 will be published on 23 February 2012 at 8.30 a.m. CET. Conference call at 3.00 p.m. CETFinancial analysts and media are invited to...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi: Presentation of Q4 and Full Year 2011 results | |
| 16.02.
| Swedish Orphan Biovitrum AB (p: ReFacto AF®/XYNTHA® Supply Agreement ... | | 2 | InvestEgate |
| 16.02.
| Swedish Orphan Biovitrum AB (publ): ReFacto AF®/XYNTHA® Supply Agreement Extended until 2020 | | 35 | Thomson Reuters ONE |
| Sobi and Pfizer have extended their supply agreement for ReFacto AF®/XYNTHA® until 31 December 2020, with an option to be further renewed. The previous agreement was due to expire in 2015. Sobi...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): ReFacto AF®/XYNTHA® Supply Agreement Extended until 2020 | |
| 06.02.
| Swedish Orphan Biovitrum AB (publ): Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs | | 60 | Thomson Reuters ONE |
| Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs | |
| 31.01.
| Swedish Orphan Biovitrum AB (publ): Sobi: Wills Hughes-Wilson appointed Vice President Government Affairs & Policy | | 42 | Thomson Reuters ONE |
| Wills Hughes-Wilson has been appointed Vice President, Government Affairs & Policy with responsibility for Sobi's contacts with all stakeholders in the health policy area. Wills comes from Genzyme...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi: Wills Hughes-Wilson appointed Vice President Government Affairs & Policy | |
| 17.01.
| Swedish Orphan Biovitrum AB (publ): Alan Raffensperger appointed Chief Operating Officer | | 36 | Thomson Reuters ONE |
| Alan Raffensperger has been appointed Chief Operating Officer (COO) of Sobi with responsibility for Sales & Marketing, Supply Chain, Procurement and IT. His most recent position was CEO of Benechill...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Alan Raffensperger appointed Chief Operating Officer | |
| 13.01.
| Swedish Orphan Biovitrum AB (publ): Sobi signs global licensing agreement for novel neonatology treatment from Only for Children Pharmaceuticals | | 50 | Thomson Reuters ONE |
| Sobi has signed a global licensing agreement with the French company Only for Children Pharmaceuticals (O4CP) regarding bumetanide reformulated for treatment of diuresis and seizures in neonates....
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi signs global licensing agreement for novel neonatology treatment from Only for Children Pharmaceuticals | |
| 10.01.
| Swedish Orphan Biovitrum AB (publ): Sobi presents today at J.P. Morgan Annual Healthcare Conference | | 36 | Thomson Reuters ONE |
| Sobi President and CEO Geoffrey McDonough today made a company presentation at the J.P. Morgan Annual Healthcare Conference in San Francisco. In his presentation Dr McDonough highlighted the newly...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi presents today at J.P. Morgan Annual Healthcare Conference | |
